Jane Street Group, LLC Corbus Pharmaceuticals Holdings, Inc. Transaction History

Jane Street Group, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 16, 2022	BUY	$0.21 - $0.53 $4,024 - $10,155	19,162 Added 29.83%	83,409 $21,000
Q1 2022 May 17, 2022	SELL	$0.32 - $0.67 $4,895 - $10,250	-15,299 Reduced 19.23%	64,247 $34,000
Q4 2021 Feb 15, 2022	BUY	$0.6 - $1.11 $37,053 - $68,549	61,756 Added 347.14%	79,546 $49,000
Q3 2021 Nov 16, 2021	SELL	$1.01 - $1.82 $10,379 - $18,704	-10,277 Reduced 36.62%	17,790 $18,000
Q2 2021 Aug 16, 2021	SELL	$1.39 - $2.21 $60,382 - $96,004	-43,441 Reduced 60.75%	28,067 $51,000
Q1 2021 May 18, 2021	BUY	$1.27 - $3.42 $23,596 - $63,543	18,580 Added 35.1%	71,508 $141,000
Q4 2020 Feb 17, 2021	SELL	$0.94 - $1.89 $32,934 - $66,219	-35,037 Reduced 39.83%	52,928 $66,000
Q3 2020 Nov 17, 2020	BUY	$1.5 - $9.38 $44,914 - $280,865	29,943 Added 51.61%	87,965 $158,000
Q2 2020 Aug 17, 2020	BUY	$4.79 - $8.39 $205,486 - $359,922	42,899 Added 283.67%	58,022 $487,000
Q1 2020 May 15, 2020	BUY	$3.44 - $7.21 $52,023 - $109,036	15,123 New	15,123 $79,000

38.7K

Ticker CRBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,268,000
Market Cap $2.62B
Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.